keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis spasticity

keyword
https://www.readbyqxmd.com/read/29149697/characteristics-of-motor-speech-phenotypes-in-multiple-sclerosis
#1
Jan Rusz, Barbora Benova, Hana Ruzickova, Michal Novotny, Tereza Tykalova, Jan Hlavnicka, Tomas Uher, Manuela Vaneckova, Michaela Andelova, Klara Novotna, Lucie Kadrnozkova, Dana Horakova
BACKGROUND: Motor speech disorders in multiple sclerosis (MS) are poorly understood and their quantitative, objective acoustic characterization remains limited. Additionally, little data regarding relationships between the severity of speech disorders and neurological involvement in MS, as well as the contribution of pyramidal and cerebellar functional systems on speech phenotypes, is available. METHODS: Speech data were acquired from 141 MS patients with Expanded Disability Status Scale (EDSS) ranging from 1 to 6...
November 8, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29145345/the-role-of-sativex-in-robotic-rehabilitation-in-individuals-with-multiple-sclerosis-rationale-study-design-and-methodology
#2
Margherita Russo, Vincenzo Dattola, Anna Lisa Logiudice, Rosella Ciurleo, Edoardo Sessa, Rosaria De Luca, Placido Bramanti, Alessia Bramanti, Antonino Naro, Rocco Salvatore Calabrò
INTRODUCTION: Currently, none of the available multiple sclerosis (MS) disease-modifying medications has been shown to stop or reverse gait disability. Recently, the nabiximols has been tested for the treatment of spasticity and walking impairment in MS. Nabiximols (trade name Sativex) is an oromucosal spray formulation containing 1:1 fixed ratio of delta-9-tetrahydrocannabinol and cannabidiol derived from cloned Cannabis sativa L. plant. METHOD AND ANALYSIS: A single-center, prospective, parallel design, single-blind trial will be conducted at the IRCCS Neurolesi "Bonino-Pulejo" (Italy) involving MS patients affected by spasticity and undergoing a Robotic Rehabilitation training...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143588/what-s-new-in-multiple-sclerosis-spasticity-research-poster-session-highlights
#3
Ralf Linker
Each year at the Multiple Sclerosis Experts Summit, relevant research in the field of multiple sclerosis spasticity is featured in poster sessions. The main studies presented at this year's meeting are summarized herein.
November 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29143586/break-out-session-highlights
#4
Kjell-Morten Myhr, Mathias Mäurer, Marisa Martínez Ginés, Federica Esposito, Ralf Linker
A popular feature of the Multiple Sclerosis Experts Summit is interactive break-out sessions to discuss various aspects of multiple sclerosis (MS), including MS spasticity and general management of MS patients. The format encourages participation and active discussion, thus providing attendees with the opportunity to exchange their experiences of the day-to-day management of MS in clinical practice. Following feedback provided by each session leader, key messages are summarized and presented in a plenary session by the Summit chair...
November 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29143581/multiple-sclerosis-symptoms-and-spasticity-management-new-data
#5
Guillermo Izquierdo
Spasticity, perceived by patients as muscle rigidity and spasms, is a common symptom in multiple sclerosis (MS). It is associated with functional impairment that can exacerbate other MS symptoms and reduce quality of life. Pharmacological treatment options are limited and frequently ineffective. Treatment adherence is a key issue to address in these patients. The efficacy and safety of 9-delta-tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray for treatment of MS spasticity were demonstrated in four Phase III trials...
November 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29135525/intrathecal-baclofen-injection-to-avoid-withdrawal-in-a-multiple-sclerosis-patient-undergoing-lumbar-spine-surgery-a-case-report
#6
Mirsad Dupanovic, Robert P Devine, Sean R Jackson, Sharon G Lynch
Spasticity of spinal or cerebral origin is frequently treated with baclofen. Treatment interruption initially results in rebound spasticity; life-threatening withdrawal symptoms may follow. Severe rebound spasticity of leg muscles occurred in a multiple sclerosis patient after a 10-hour long perioperative pause of oral baclofen intake. In a subsequent spine surgery, recurrence was prevented by substituting a cumulative 12-hour oral baclofen dose with an intraoperative intrathecal injection. Administration of intrathecal baclofen during prolonged surgery in patients dependent on oral baclofen may improve patient comfort and prevent early withdrawal symptoms...
November 9, 2017: A & A Case Reports
https://www.readbyqxmd.com/read/29134767/availability-and-approval-of-cannabis-based-medicines-for-chronic-pain-management-and-palliative-supportive-care-in-europe-a-survey-of-the-status-in-the-chapters-of-the-european-pain-federation
#7
N Krcevski-Skvarc, C Wells, W Häuser
BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care...
November 13, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29119763/-systematic-review-of-safeness-and-therapeutic-efficacy-of-cannabis-in-patients-with-multiple-sclerosis-neuropathic-pain-and-in-oncological-patients-treated-with-chemotherapy
#8
REVIEW
Laura Amato, Silvia Minozzi, Zuzana Mitrova, Elena Parmelli, Rosella Saulle, Fabio Cruciani, Simona Vecchi, Marina Davoli
BACKGROUND: medical cannabis refers to the use of cannabis or cannabinoids as medical therapy to treat disease or alleviate symptoms. In the United States, 23 states and Washington DC (May 2015) have introduced laws to permit the medical use of cannabis. Within the European Union, medicinal cannabis laws and praxis vary wildly between Countries. OBJECTIVES: to provide evidence for benefits and harms of cannabis (including extracts and tinctures) treatment for adults in the following indications: control of spasticity and pain in patients with multiple sclerosis; control of pain in patients with chronic neuropathic pain; control of nausea and vomiting in adults with cancer receiving chemotherapy...
September 2017: Epidemiologia e Prevenzione
https://www.readbyqxmd.com/read/29115915/neuromodulation-in-multiple-sclerosis
#9
Hesham Abboud, Eddie Hill, Junaid Siddiqui, Alessandro Serra, Benjamin Walter
Neuromodulation, or the utilization of advanced technology for targeted electrical or chemical neuronal stimulation or inhibition, has been expanding in several neurological subspecialties. In the past decades, immune-modulating therapy has been the main focus of multiple sclerosis (MS) research with little attention to neuromodulation. However, with the recent advances in disease-modifying therapies, it is time to shift the focus of MS research to neuromodulation and restoration of function as with other neurological subspecialties...
November 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29109461/oral-administration-of-cannabis-with-lipids-leads-to-high-levels-of-cannabinoids-in-the-intestinal-lymphatic-system-and-prominent-immunomodulation
#10
Atheer Zgair, Jong Bong Lee, Jonathan C M Wong, Dhiaa A Taha, Jehan Aram, Daisy Di Virgilio, Joshua W McArthur, Yu-Kit Cheng, Ivo M Hennig, David A Barrett, Peter M Fischer, Cris S Constantinescu, Pavel Gershkovich
Cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lymphatic transport in rats. CBD concentrations in the lymph were 250-fold higher than in plasma, while THC concentrations in the lymph were 100-fold higher than in plasma. Since cannabinoids are currently in clinical use for the treatment of spasticity in multiple sclerosis (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients, lymphocytes from those patients were used to assess the immunomodulatory effects of cannabinoids...
November 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29097192/the-endocannabinoid-system-and-its-therapeutic-exploitation-in-multiple-sclerosis-clues-for-other-neuroinflammatory-diseases
#11
REVIEW
Valerio Chiurchiù, Mario van der Stelt, Diego Centonze, Mauro Maccarrone
Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a still unmet need for new treatment options, especially for the progressive forms of the disease. Both preclinical and clinical data suggest that cannabinoids, derived from the Cannabis sativa plant, may be used to control symptoms such as spasticity and chronic pain, whereas only preclinical data indicate that these compounds and their endogenous counterparts, i...
October 31, 2017: Progress in Neurobiology
https://www.readbyqxmd.com/read/29069950/the-cross-cultural-adaptation-and-psychometric-validation-of-the-msss-88-for-use-in-italian-patients-with-multiple-sclerosis
#12
Marcella Ottonello, Leonardo Pellicciari, Diego Centonze, Calogero Foti, Caterina Pistarini, Caterina Albensi, Andrea Giordano
PURPOSE: To cross-culturally translate the Multiple Sclerosis Spasticity Scale into Italian and to evaluate its psychometric properties in patients with multiple sclerosis. METHODS: The Italian version of Multiple Sclerosis Spasticity Scale was developed in accordance with international standards and subsequently administered to 232 Italian adults with multiple sclerosis. The following psychometric properties were analyzed: internal consistency through Cronbach's α and item-to-total correlation, dimensionality with factor analysis, and convergent and criterion validity through hypotheses-testing, comparing the Multiple Sclerosis Spasticity Scale with other outcome measures (Fatigue Severity Scale, Multiple Sclerosis Quality of Life, Modified Ashworth Scale, Barthel Index, and Expanded Disability Status Scale) and analyzing related constructs...
October 25, 2017: Disability and Rehabilitation
https://www.readbyqxmd.com/read/29067992/medical-cannabis-for-the-treatment-of-chronic-pain-and-other-disorders-misconceptions-and-facts
#13
Kevin P Hill, Matthew D Palastro
Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession, medical cannabis legalization, and legalization of recreational cannabis.  In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis.  While cannabis and cannabinoids continue to be evaluated as pharmacotherapy for medical conditions, currently, the best evidence exists for the following medical conditions: chronic pain, neuropathic pain, and spasticity resulting from multiple sclerosis...
October 25, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29063259/-what-is-new-in-symptomatic-ms-treatment-part%C3%A2-2-gait-disorder-and-spasticity
#14
REVIEW
T Henze, W Feneberg, P Flachenecker, D Seidel, H Albrecht, M Starck, S G Meuth
The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKN‑MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place...
October 23, 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/29055461/sativex-in-the-management-of-multiple-sclerosis-related-spasticity-an-overview-of-the-last-decade-of-clinical-evaluation
#15
REVIEW
Sabrina Giacoppo, Placido Bramanti, Emanuela Mazzon
BACKGROUND: Spasticity is a common symptom of multiple sclerosis (MS) affecting about 80% of MS patients. Numerous lines of evidence suggest that spasticity due to its complexity is not adequately managed with conventional anti-spastic therapies. Therefore, in order to improve the outcomes for the majority of MS patients, alternative approaches are needed to be discovered. Over the last years, the use of cannabinoid compounds as a potential treatment for MS-related symptoms has aroused great interest, owing to encouraging preclinical and clinical studies...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29055458/the-walking-speed-reserve-in-low-disabled-people-with-multiple-sclerosis-does-it-provide-greater-insight-in-detecting-mobility-deficits-and-risk-of-falling-than-preferred-and-fast-walking-speeds
#16
Alon Kalron, Shay Menascu, Mark Dolev, Uri Givon
The extent of an increase from a preferred walking speed (PWS) to a fast walking speed (FWS) is defined as the walking speed reserve (WSR). The WSR is unique as it reflects an individual's ability to increase their walking speed on demand. The primary objective of this study was to examine whether the WSR was more advantageous than the PWS and FWS in terms of reflecting mobility deficits and risk of falling associated with multiple sclerosis (MS). The patient group included 235 people with MS (PwMS) (139 women) with a mean age of 43...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29055449/successful-long-term-management-of-spasticity-in-patients-with-multiple-sclerosis-using-a-software-application-app-a-pilot-study
#17
Rainer Ehling, Michael Edlinger, Kay Hermann, Kerstin Dröge, Yvonne Seidinger, Ursula Miller, Hannes Franz Alber, Christian Brenneis
BACKGROUND: Spasticity is a very common syndrome in patients with multiple sclerosis (pwMS), but available treatments lead to sufficient symptom control only in one third. OBJECTIVE: To investigate the impact of an individualized training program on improving spasticity in a prospective pilot trial in pwMS suffering from moderate spasticity (defined as ≥ 4 on a normative rating scale; NRS). METHODS: PwMS were familiarized with predefined exercises targeting spasticity while undergoing inpatient rehabilitation (IR)...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29055439/patient-perspectives-on-neuromyelitis-optica-spectrum-disorders-data-from-the-patientslikeme-online-community
#18
Stephanie Eaneff, Victor Wang, Morgan Hanger, Michael Levy, Maureen A Mealy, Alexander U Brandt, Daniel Eek, John N Ratchford, Fredrik Nyberg, Jonathan Goodall, Paul Wicks
BACKGROUND: Few studies have evaluated patient perspectives on neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). OBJECTIVE: Describe patient-reported clinical and treatment experience in NMOSD and compare disease characteristics of NMOSD with those of multiple sclerosis (MS). METHODS: This retrospective, observational study included 522 members with NMO or NMOSD (hereafter collectively referred to as NMOSD) from PatientsLikeMe (PLM), an online patient community...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29055436/brain-white-matter-demyelinating-lesions-and-amyotrophic-lateral-sclerosis-in-a-patient-with-c9orf72-hexanucleotide-repeat-expansion
#19
Miguel Oliveira Santos, Inês Caldeira, Marta Gromicho, Ana Pronto-Laborinho, Mamede de Carvalho
A hexanucleotide repeat expansion in the C9orf72 gene is associated with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. It has been described before four patients with multiple sclerosis (MS) and C9orf72-ALS. However, C9orf72 positivity is not associated with increased risk of MS. Inflammatory pathways related to NF-κB have been linked to ALS and MS, and appear to be important in C9orf72-ALS patients. A 42-year-old woman presented with progressive bulbar symptoms for 9 months. Neurological examination disclosed spastic dysarthria, atrophic tongue with fasciculations, brisk jaw and limb tendon reflexes, and bilateral Hoffman sign...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29052091/thc-cbd-oromucosal-spray-in-patients-with-multiple-sclerosis-overactive-bladder-a-pilot-prospective-study
#20
Giorgia Teresa Maniscalco, R Aponte, D Bruzzese, G Guarcello, V Manzo, M Napolitano, O Moreggia, F Chiariello, C Florio
Lower urinary tract dysfunctions (LUTDs) are commonly reported in multiple sclerosis (MS) patients and are mainly related to neurogenic overactive bladder (OAB). The aim of this observational study was to assess the effect of a tetrahydrocannabinol-cannabidiol (THC/CBD) oromucosal spray on resistant OAB by means of clinical and instrumental tools. Twenty-one MS patients were screened, and 15 cases have been evaluated. They underwent a specific clinical assessment (overactive bladder symptom score, OABSS) and a urodynamic assessment evaluating the maximal cystometric capacity (CCmax), bladder compliance (Qmax), maximum detrusor pressure (Pdet max), detrusor pressure at the first desire (Pdet first), bladder volume at the first desire (BVFD), leakage volume (LV), and post-void residual volume (PVR), before and after 4 weeks of THC/CBD administration...
October 19, 2017: Neurological Sciences
keyword
keyword
60033
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"